An observational study in Prolapse, Sacrocolpopexy and Pelvic Organ Prolapse (POP), sponsored by A.M.I. Agency for Medical Innovations GmbH. Completed at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by A.M.I. Agency for Medical Innovations GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Pelvic Organ Prolapse with a site in Germany — 4 open to participants now, 6 under way, none of them phase 3. Pelvic Organ Prolapse · Germany.
Among the 19 studies in Pelvic Organ Prolapse with a site in Germany, this one is the 10th largest by enrollment of the 14 observational ones that give a count, is one of 2 that started in 2024, is one of 14 observational ones, and was the 17th registered.
522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.
Browse Pelvic Organ Prolapse studies →4 of the 19 studies in Pelvic Organ Prolapse with a site in Germany are open now. Recruiting first, the newest first:
A.M.I. Agency for Medical Innovations GmbH · Sites in Germany, Austria
Ages 18–80 · Women only
A.M.I. Agency for Medical Innovations GmbH · Sites in Germany, Austria
Ages 18+ · Women only
Promedon · Sites in Germany
Ages 18+ · Women only
Ethicon, Inc. · Sites in Germany, United States, Austria and 4 more countries
Ages 21+ · Women only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2024.
This study's enrollment of 80 is below the median of 134 across 171 observational studies indexed under Pelvic Organ Prolapse.
Median enrollment 85 across the 5 interventional studies, 113 across the 14 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
A.M.I. Agency for Medical Innovations GmbH is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
A.M.I. Agency for Medical Innovations GmbH has 4 studies filed under Pelvic Organ Prolapse — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Pelvic Organ Prolapse with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The retrospective patient chart review aims to generate additional data to substantiate the safety and performance of EndoGYNious and PelviGYNious.
522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.
This study's enrollment of 80 is below the median of 134 across 171 observational studies indexed under Pelvic Organ Prolapse.
Browse Pelvic Organ Prolapse studies →A.M.I. Agency for Medical Innovations GmbH is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Compared within Pelvic Organ Prolapse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Prolapse. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The planned clinical investigation is a retrospective chart review of clinical data.
All patients who underwent surgery between January 2016 and December 2023 and met the inclusion criteria and no exclusion criteria were analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who rule out subsequent contact by the hospital will be excluded.
The use of the products is in case of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient received EndoGYNious mesh implant.
Device: EndoGYNious
Patient received PelviGYNious mesh implant.
Device: PelviGYNious
Patient received PelviGYNious implant.
Patient received EndoGYNious implant.
Patient subjective outcome
Patient subjective outcome after POP treatment with EndoGYNious or PelviGYNious will be measured with a validated questionnaire (German Pelvic Floor Questionnaire "Deutscher Beckenboden-Fragebogen") . This questionnaire focus on 4 items (bladder, bowel, prolapse, sexuality). Each item has its scores, scores were summed up for each category (bladder max. 45, bowel max. 34, prolapse max. 15, sexual max. 21), Calculation: (achieved value of category/ max. value of category)\*10; max. value 10 for each category, max. final score 40 The postoperative scores will be compared with the preoperative scores.
Time frame: From baseline to the end of last follow-up [3 months, 12 months]
Postoperative complications
To analyze postoperative complications in women undergoing POP treatment with EndoGYNious or PelviGYNious during the follow up period. The occurrence of each complicaiton/adverse event will be compared to the occurrence of the same complication by similar products or other state of the art treatments
Time frame: From baseline to the end of last follow-up [average of minimum 3 months]
Anatomical success (POP-Q)
POP-Q system according to ICS with POP-Q stages 0, I, II, III, IV The postoperative POP-Q stages (overall, apical compartment, anterior compartment, posterior compartment) will be compared to the preoperative POP-Q stages.
Time frame: From baseline to the end of last follow-up [average of minimum 3 months]
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2024 to primary completion in Dec 2025, 20 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion May 2025 → Dec 2025 and completion Aug 2025 → Feb 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
A.M.I. Agency for Medical Innovations GmbH